Zacks: Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $26.81 Million

Equities analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to announce sales of $26.81 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $11.00 million and the highest estimate coming in at $67.93 million. Alnylam Pharmaceuticals reported sales of $18.96 million in the same quarter last year, which indicates a positive year-over-year growth rate of 41.4%. The business is scheduled to issue its next earnings report on Friday, May 4th.

On average, analysts expect that Alnylam Pharmaceuticals will report full year sales of $26.81 million for the current financial year, with estimates ranging from $13.74 million to $139.60 million. For the next year, analysts anticipate that the company will post sales of $291.98 million per share, with estimates ranging from $213.30 million to $435.03 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The business had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. During the same period last year, the business earned ($1.32) earnings per share. The company’s quarterly revenue was up 116.6% on a year-over-year basis.

Several equities research analysts recently commented on ALNY shares. Goldman Sachs Group raised Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 17th. B. Riley dropped their price objective on Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a research report on Thursday, November 9th. Finally, BidaskClub cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $126.76.

In other news, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total value of $4,835,274.55. Following the transaction, the vice president now owns 6,352 shares of the company’s stock, valued at $835,859.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Laurie Keating sold 6,249 shares of the firm’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the transaction, the senior vice president now directly owns 17,749 shares in the company, valued at approximately $2,151,178.80. The disclosure for this sale can be found here. Insiders sold 72,994 shares of company stock worth $9,669,353 over the last three months. Insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 167 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Alnylam Pharmaceuticals by 0.4% in the third quarter. Dimensional Fund Advisors LP now owns 180,058 shares of the biopharmaceutical company’s stock worth $21,156,000 after buying an additional 629 shares during the period. Great West Life Assurance Co. Can raised its stake in shares of Alnylam Pharmaceuticals by 8.5% in the third quarter. Great West Life Assurance Co. Can now owns 8,904 shares of the biopharmaceutical company’s stock worth $1,050,000 after buying an additional 695 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 10.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock worth $915,000 after buying an additional 700 shares during the period. Finally, Public Employees Retirement Association of Colorado raised its stake in shares of Alnylam Pharmaceuticals by 4.4% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 17,321 shares of the biopharmaceutical company’s stock worth $2,201,000 after buying an additional 736 shares during the period. 88.61% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $120.83 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. Alnylam Pharmaceuticals has a 12-month low of $45.00 and a 12-month high of $147.63.

COPYRIGHT VIOLATION WARNING: This report was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2018/02/21/zacks-brokerages-anticipate-alnylam-pharmaceuticals-inc-alny-will-post-quarterly-sales-of-26-81-million.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply